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Abstract
Introduction: Pulmonary arterial hypertension (PAH) is an serious lifethreatening and severe 
complication of HIV infection. PAH Presentation in patient in HIV tend to non specifi c, resulted 
in recognized diagnosis at a later stage. Pulmonary Hypertension Associated with HIV Infection 
(PH-HIV) has been documented to occur at all stages of the disease and its manifestations 
range from asymptomatic right ventricular dysfunction to overt right heart failure. We presented 
this case to highlight the cardiovascular complication of HIV.
Case report
Case: A 9 years old child came to pediatric clinic with chief complaint a worsening dyspneu 
for 1 month, leg edema and diffi culty lying on a fl at bed. Patient was already diagnosed as 
HIV infection since three years old and regularly take HAART. At physical examination patient 
look dyspneic, heart rate 120 bpm, respiratory rate 40 times per minute, peripheral oxygen 
saturation 58% on room air, cyanotic lips and fi ngers, leg edema, chest examination showed 
RV heaving, with no cardiac murmur, rales heard at both lung, abdomen examination showed 
hepatomegaly and ascites. ECG fi ndings sinus rythm, right axis deviation, right ventricular 
hypertrophy. Echocardiography fi ndings showed right ventricular and atrial enlargement, mild 
to moderate tricuspid regurgitation ( TVG 50 mmHg, TR velocity 3.6 m/s), mild pulmonary 
regurgitation, Ejection fraction normal, TAPSE 8, no cardiac shunts found. Blood examination 
showed CD 4 84 cell/μL. Patient treated with furosemid 20 mg/8 hours, spironolacton 12.5 
mg/24 hour, lisinopril 2 mg/12 hours, sidenafi l 7 mg/8 hours, and HAART duviral ½ tab/12 
hours, aluvia 1 tab/12 hours. Patient treated at pediatric ward for 3 weeks and discharged in 
relieved condition and symptoms.
Discussion: PH-HIV histopathologic characteristics are not different from those idiopathic PH. 
Pulmonary vascilature is obliterated with medial hypertrophy and increased proliferation of 
endothelial and smooth muscle cells. Plexiforms lesions can be detected in 78% patient with 
HIV PH. Whether there is no evidence that HIV was found infected lung vasculature but virus’s 
protein and their interactions are strong candidate for cause-effect relationship between PH 
and HIV. HIV plays role by means of chronic infl amation and immune activation produced by 
HIV infection may lead increased secretion proinfl amatory cytokines and growth factors that 
may promote PAH. Majority of the patients clinically present withdyspnoea on exertion (85%), 
pedal oedema (20-30%)and a non-productive cough (19%). ECG fi nding that may support the 
diagnosis of PH is right axis deviation, P pulmonal, right ventricular hypertrophy, right bundle 
branch block, and prolonged QT interval. Echocardiography is the non invasive test of choice for 
initial screening for PH in symptomatic HIV patients. It is useful for  identifying potential causes 
of PH, evaluating RV function, and assessing related comorbidities. Treatment for HIV-PH use 
the same algorithm with PAH and should considered and taking considerations co-morbidities 
and drug interactions.
Conclusion:  PH-HIV is an important cardiovascular complication of HIV infection. The early 
initial diagnosis and treatment may improve functional class and symptoms.
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